London, UK – [Insert Current Date, e.g., July 24, 2024] – In a landmark decision poised to significantly alter the landscape of cardiovascular care, the UK’s National Institute for Health and Care Excellence (NICE) has officially recommended Bayer’s innovative non-steroidal drug, Kerendia (finerenone), for use within the National Health Service (NHS) in England. This crucial endorsement targets patients suffering from chronic heart failure (CHF) with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), a challenging condition marked by high rates of hospitalisation and a considerable burden on both patients and the healthcare system.
n
Following the anticipated release of NICE’s final draft guidance in August 2026, Kerendia will become available to an estimated 280,000 eligible English patients, offering a new, highly selective treatment option. This move is expected to not only enhance patient quality of life but also to yield substantial cost savings for the NHS by reducing the incidence of avoidable emergency hospital admissions, a persistent challenge in heart failure management.
n
Kerendia, a next-generation mineralocorticoid receptor antagonist (MRA), operates through a distinct mechanism by reducing vascular inflammation and the scarring induced by mineralocorticoid signalling in the muscular layer of the heart wall. Furthermore, it helps alleviate the heart’s workload by diminishing sodium retention in the kidneys, thereby reducing excess fluid burden. This recommendation expands Kerendia’s role within the NHS, as it was previously approved by NICE in 2023 for adult patients with stage 3 or 4 chronic kidney disease (CKD) linked to type 2 diabetes, provided they exhibited albuminuria.
n
The decision underscores a concerted effort by UK health authorities to integrate advanced, evidence-based therapies into standard care, particularly for conditions like heart failure that continue to pose significant public health challenges. With heart failure being a leading cause of avoidable hospitalisations, the introduction of Kerendia represents a strategic intervention to improve patient outcomes and optimize healthcare resource allocation.
n
A New Horizon for Heart Failure Treatment
n
Heart failure, a complex and debilitating condition, affects approximately 635,000 patients across England. Of these, roughly half suffer from preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), a subtype that has historically presented significant treatment challenges due to its heterogeneous nature and the lack of highly effective targeted therapies. Unlike heart failure with reduced ejection fraction (HFrEF), where the heart muscle is weakened and cannot pump enough blood, HFpEF involves a stiffening of the heart muscle, preventing it from filling properly.
n
Addressing a Critical Unmet Need
n
For decades, the treatment landscape for HFpEF/HFmrEF has lagged behind that of HFrEF, leaving many patients with limited therapeutic options. Traditional approaches often focused on managing symptoms with diuretics, beta-blockers, and ACE inhibitors, but these rarely addressed the underlying pathophysiology effectively. The introduction of SGLT2 inhibitors like Jardiance (empagliflozin) and Forxiga (dapagliflozin) in 2023 marked a significant advancement, yet a substantial unmet need remained for patients who might not respond to these therapies or require additional interventions.
n
Kerendia steps into this gap as a non-steroidal MRA, offering distinct advantages over older, steroidal MRAs such as spironolactone and eplerenone, which are also available through the NHS. While traditional MRAs have proven beneficial, their steroidal structure can lead to a higher incidence of side effects, including hyperkalemia (elevated potassium levels) and sex hormone-related issues like gynecomastia in men and menstrual irregularities in women. Kerendia’s non-steroidal, highly selective profile means it can target the mineralocorticoid receptor with greater precision, potentially leading to a lower rate of these undesirable side effects. This selectivity is particularly important for patients who might be more susceptible to hyperkalemia or who find the sexual side effects of older drugs intolerable, thereby broadening the eligible patient population.
n
The Regulatory Journey: From Development to Approval
n
Bayer’s development of finerenone (Kerendia) represents years of dedicated research into novel pathways for cardiovascular and renal protection. Its journey through clinical trials has been meticulously documented, culminating in a series of pivotal studies that demonstrated its efficacy and safety across different patient populations. The drug’s unique mechanism of action, targeting both inflammation and fibrosis, distinguished it early on as a promising candidate for conditions where these processes play a critical role, such as chronic kidney disease and heart failure. The successful navigation of stringent regulatory processes, both in the UK and globally, underscores the robust evidence base supporting its use.
n
The Chronology of Kerendia’s Path to NHS
n
The journey of Kerendia from a promising molecule in Bayer’s pipeline to a recommended treatment on the NHS is a testament to rigorous scientific inquiry, extensive clinical development, and a comprehensive regulatory review process.
n
Early Development and Pivotal Trials
n
Bayer’s research into finerenone focused on developing a selective MRA that could offer cardiovascular and renal benefits with an improved safety profile, particularly concerning hyperkalemia. This led to a series of large-scale, international, phase III clinical trials:
n
- n
- FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease): This study, involving over 5,700 patients with chronic kidney disease and type 2 diabetes, demonstrated that finerenone significantly reduced the risk of kidney failure, cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Its positive outcomes laid the groundwork for its initial regulatory approvals.
- FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease): Complementing FIDELIO-DKD, FIGARO-DKD enrolled over 7,400 patients and further confirmed finerenone’s cardiovascular benefits in a broader range of patients with type 2 diabetes and chronic kidney disease, showing reductions in cardiovascular death and non-fatal cardiovascular events.
- FINEARTS-HF (Finerenone in Patients with Heart Failure and Preserved Ejection Fraction): This pivotal trial, which specifically supported the recent NICE recommendation for heart failure, investigated the efficacy and safety of finerenone in over 6,000 patients with symptomatic HFpEF. The trial demonstrated a significant reduction in the composite primary endpoint of cardiovascular death or total heart failure events (hospitalisations or urgent heart failure visits) compared to placebo. These findings were critical in establishing Kerendia as a viable treatment option for a patient population that historically had limited disease-modifying therapies. The trial highlighted the drug’s ability to improve cardiovascular outcomes without a significant increase in adverse events, including hyperkalemia, which was carefully managed and occurred at a lower rate than often seen with steroidal MRAs.
n
n
n
n
These trials collectively provided the robust evidence base necessary for regulatory submissions globally, including to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), leading to approvals in various regions for both chronic kidney disease associated with type 2 diabetes and, more recently, for heart failure.
n
Navigating the UK Regulatory Landscape
n
In the UK, the path to NHS availability involves several key stages:
n
- n
- MHRA Approval: Before a drug can be considered by NICE, it must first receive marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). This ensures the drug meets stringent standards for safety, quality, and efficacy. Kerendia received its MHRA marketing authorisation for its various indications prior to NICE’s appraisals.
- NICE Appraisal for CKD/T2D (2023): Based on the strong evidence from FIDELIO-DKD and FIGARO-DKD, NICE conducted an appraisal for Kerendia’s use in chronic kidney disease linked to type 2 diabetes. This culminated in its recommendation in 2023, making it available to eligible patients in England with albuminuria. This initial approval established Kerendia’s value within the NHS framework.
- Current NICE Appraisal for HFpEF/HFmrEF: Following the successful FINEARTS-HF trial, Bayer submitted Kerendia for appraisal specifically for chronic heart failure with preserved or mildly reduced ejection fraction. The NICE appraisal process is comprehensive, involving a review of clinical effectiveness, cost-effectiveness, and impact on patient quality of life. This includes:n
- n
- Evidence Review: Independent assessment of all submitted clinical trial data and economic models.
- Stakeholder Consultation: Input from patient groups, healthcare professionals, and the pharmaceutical company.
- Draft Guidance: Publication of preliminary recommendations for public and stakeholder comment.
- Final Guidance: The issuance of the definitive recommendation. The agency expects to publish its final draft guidance in August 2026, solidifying Kerendia’s place in the NHS formulary for heart failure.
n
- Role of the Aligned Pathway: This decision also highlights the efficacy of the aligned pathway launched by the MHRA and NICE in March 2026. This initiative was designed to expedite the medicines regulation process in the UK by fostering greater collaboration and simultaneous review, aiming to bring innovative treatments to patients faster. Kerendia’s timely recommendation for a complex condition like HFpEF/HFmrEF underscores the potential success of this streamlined approach in accelerating patient access to vital medicines.
n
n
Once the final guidance is issued in August 2026, NHS England will work to integrate Kerendia into local treatment pathways and formularies, ensuring that eligible patients can access the drug as quickly as possible.
Supporting Data: The Burden of Heart Failure and Kerendia’s Impact
The NICE recommendation for Kerendia is not merely a pharmaceutical endorsement; it is a strategic response to a pressing public health crisis – the escalating burden of heart failure in England.
The Pervasive Challenge of Heart Failure in England
Heart failure, regardless of ejection fraction, represents a significant drain on healthcare resources and profoundly impacts patient lives. NICE estimates that 635,000 patients across England are living with heart failure. A staggering 100,000 hospitalisations were linked to heart failure between 2023 and 2024 alone. These figures highlight heart failure as one of the leading causes of avoidable hospital admissions, a metric that carries immense economic and human costs.
The economic cost of heart failure to the NHS is substantial, driven primarily by frequent and prolonged hospital stays. Each hospitalisation for heart failure can cost the NHS thousands of pounds, not including the long-term care and rehabilitation required. Beyond the financial implications, the human cost is immeasurable. Patients with heart failure often experience severe symptoms such including breathlessness, fatigue, and swelling, which significantly diminish their quality of life, limit daily activities, and contribute to psychological distress. Furthermore, heart failure carries a poor prognosis, with mortality rates comparable to some cancers. For HFpEF/HFmrEF patients, the diagnostic and management challenges are amplified by the diverse underlying causes and the lack of a "one-size-fits-all" treatment. The existing treatment landscape, while evolving, still leaves many patients struggling with persistent symptoms and a high risk of adverse events.
Clinical Evidence: A Deeper Look at Kerendia’s Efficacy
The NICE recommendation is firmly rooted in the robust clinical evidence generated by the FINEARTS-HF trial. This study demonstrated Kerendia’s ability to significantly improve clinical outcomes for patients with HFpEF/HFmrEF. The primary endpoint, a composite of cardiovascular death or total heart failure events (hospitalisations or urgent visits), showed a statistically significant reduction in the group treated with finerenone compared to placebo. This finding is critical as it directly addresses the key drivers of morbidity and mortality in heart failure.
Secondary endpoints from FINEARTS-HF also provided compelling evidence of benefit. For instance, the trial showed a reduction in the risk of first and recurrent heart failure hospitalisations, a direct contributor to the "avoidable hospitalisations" statistic highlighted by NICE. The safety profile observed in FINEARTS-HF was also favorable. While hyperkalemia is a known risk with MRAs, the incidence of severe hyperkalemia in the finerenone group was manageable and comparable to what was expected, and notably lower than often observed with traditional steroidal MRAs. This improved safety profile, particularly the lower risk of sex hormone-related side effects due to its non-steroidal nature, makes Kerendia a more attractive option for a wider range of patients, enhancing adherence and long-term treatment success.
Economic Evaluation and Cost-Effectiveness
NICE’s decision-making process inherently includes a rigorous economic evaluation, assessing whether a new treatment offers sufficient value for money to the NHS. This involves calculating Quality-Adjusted Life Years (QALYs) and considering the overall budget impact. For Kerendia, the economic modeling would have factored in the acquisition cost of the drug against the potential savings generated by reducing hospitalisations and improving patient health.
By reducing the risk of cardiovascular death and heart failure hospitalisations, Kerendia is projected to lead to substantial downstream savings for the NHS. Fewer hospital admissions mean less pressure on acute care beds, emergency departments, and specialist heart failure nurses. These savings, combined with the improved quality of life for patients, contribute to a positive cost-effectiveness ratio, aligning with NICE’s mandate to recommend interventions that are both clinically effective and economically viable for the public health system. The ability of Kerendia to treat an estimated 280,000 patients further amplifies its potential economic impact.
Official Responses and Stakeholder Perspectives
The NICE recommendation for Kerendia has been met with widespread approval from various stakeholders, reflecting the significant unmet need it addresses and its potential to transform patient care.
NICE’s Vision for Patient Care and NHS Efficiency
Helen Knight, NICE’s Director of Medicines Evaluation, articulated the dual benefits of this decision: “Kerendia not only holds the potential to help boost patient quality of life, but it also offers the chance to save the NHS money and free up space by diminishing the risk of hospitalisation for unplanned emergency treatment.” This statement encapsulates NICE’s strategic objectives: to improve patient outcomes through access to innovative medicines while simultaneously ensuring fiscal responsibility and enhancing the overall efficiency of the NHS. The agency’s endorsement of Kerendia aligns with its broader commitment to supporting interventions that offer clear clinical advantages and contribute positively to the sustainability of the healthcare system. For NICE, this decision represents a successful navigation of the complex balance between innovation, cost, and patient benefit, especially for a condition that has historically been a significant burden on acute care services.
Bayer’s Commitment to Cardiovascular Health
Bayer, as the developer of Kerendia, has expressed profound satisfaction with NICE’s decision. A hypothetical statement from a Bayer representative, such as a Head of Pharmaceuticals UK, might read: "We are immensely proud that NICE has recognised the transformative potential of Kerendia for patients living with chronic heart failure in England. This recommendation is a testament to years of dedicated research and development aimed at addressing critical unmet needs in cardiovascular and renal health. Kerendia offers a new hope for patients with HFpEF/HFmrEF, a population that has long awaited more effective treatment options. We are committed to working closely with the NHS to ensure that eligible patients can access this innovative medicine as quickly as possible, ultimately improving lives and contributing to the sustainability of the healthcare system." This sentiment reflects Bayer’s strategic focus on delivering breakthrough therapies that provide significant clinical value and improve patient outcomes globally.
Voices from the Medical Community
Leading cardiologists and heart failure specialists have welcomed the news, recognizing Kerendia as a valuable addition to their therapeutic arsenal. A hypothetical quote from a prominent cardiologist might state: "For too long, managing heart failure with preserved or mildly reduced ejection fraction has been a challenge, with limited disease-modifying treatments. Kerendia’s non-steroidal nature and demonstrated efficacy in reducing cardiovascular events and hospitalisations represent a significant step forward. This drug offers us a new tool to not only alleviate symptoms but also to fundamentally alter the disease trajectory for our patients, with a favourable safety profile that expands its applicability. It will undoubtedly improve our ability to provide comprehensive care and enhance patient outcomes." This reflects the medical community’s eagerness for more effective treatments for a patient group that often has a complex disease presentation.
Patient Advocacy: A Welcome Breakthrough
Patient advocacy groups, representing individuals living with heart failure, have also voiced their enthusiasm. A hypothetical statement from a charity like the British Heart Foundation could be: "This is truly fantastic news for the hundreds of thousands of people in England living with heart failure. The availability of Kerendia offers new hope for improved quality of life, reduced hospital visits, and potentially a longer, healthier future. For too many, heart failure has meant a life of constant concern and frequent disruptions due to hospitalisations. This decision by NICE is a monumental step towards ensuring that more patients have access to the best possible care, and we applaud all involved in bringing this vital medicine to the NHS." Such statements highlight the tangible impact of these decisions on the lives of patients and their families, who often bear the brunt of chronic illness.
Broader Implications and Future Outlook
The NICE recommendation for Kerendia extends beyond its immediate impact on individual patients and the NHS; it carries significant implications for healthcare delivery, pharmaceutical innovation, and future policy.
Transforming Patient Lives and Healthcare Delivery
For patients with HFpEF/HFmrEF, Kerendia offers a tangible prospect of a better quality of life. Reduced hospitalisations mean less time spent away from family and work, fewer invasive medical procedures, and a diminished psychological burden associated with acute health crises. The drug’s improved side-effect profile, particularly the lower risk of sex hormone-related issues compared to older MRAs, is also a crucial factor in patient adherence and overall well-being. This will enable healthcare professionals to offer a more personalized treatment approach, tailoring therapies to individual patient needs and tolerability. The integration of Kerendia into existing care pathways will necessitate updated clinical guidelines and ongoing education for cardiologists, general practitioners, and specialist heart failure nurses to ensure optimal prescribing and patient management.
Strategic Impact on the NHS
The potential for significant cost savings from reduced hospital admissions is a critical strategic benefit for the NHS. In an era of increasing demand and constrained budgets, interventions that can "save the NHS money and free up space" are invaluable. These savings can then be reallocated to other priority areas, strengthening other aspects of healthcare provision. Furthermore, by reducing the burden of acute heart failure events, Kerendia can help shift the focus from reactive emergency care to proactive, preventative management, aligning with broader NHS strategies for chronic disease management. This decision reinforces the NHS’s commitment to adopting innovative therapies that offer both clinical effectiveness and economic value.
A Catalyst for Pharmaceutical Innovation
For the pharmaceutical industry, the NICE recommendation for Kerendia reinforces the value of targeted therapies, particularly for conditions with high unmet needs. It signals that the UK market is receptive to novel compounds that demonstrate clear clinical benefits and cost-effectiveness. This decision, alongside the successful implementation of the aligned pathway between the MHRA and NICE, could serve as a powerful incentive for pharmaceutical companies to prioritize the UK for future drug launches and clinical development. The aligned pathway aims to streamline the regulatory and appraisal processes, ensuring that groundbreaking medicines can reach patients faster, thereby fostering a more dynamic and responsive healthcare innovation ecosystem in the UK. Kerendia’s journey through this expedited pathway sets a precedent for how future innovative drugs might be assessed and integrated.
The Road Ahead for Kerendia
Looking ahead, the availability of Kerendia will be followed by continued monitoring and evaluation. Real-world evidence studies will be crucial to understand its long-term effectiveness and safety in a broader, more diverse patient population outside of controlled clinical trial settings. Such studies can provide valuable insights into optimal prescribing patterns, adherence rates, and the drug’s impact on patient-reported outcomes in routine clinical practice. There may also be ongoing research into Kerendia’s potential for other indications or in combination with other therapies, further expanding its therapeutic utility. The long-term impact on the epidemiology of heart failure and associated comorbidities will be a key area of interest for public health researchers.
Conclusion
The NICE recommendation of Bayer’s Kerendia for chronic heart failure with preserved or mildly reduced ejection fraction marks a pivotal moment in cardiovascular medicine in England. It offers a new, effective, and safer treatment option for a substantial patient population that has long faced limited therapeutic choices. Beyond its direct clinical benefits of reducing cardiovascular death and heart failure hospitalisations, Kerendia promises to deliver significant economic advantages to the NHS by alleviating the immense burden of avoidable admissions. This decision not only champions patient quality of life but also underscores the UK’s commitment to integrating pharmaceutical innovation with strategic healthcare planning. As Kerendia becomes available to eligible patients from August 2026, it is poised to usher in a new era of hope and improved outcomes for those living with chronic heart failure across England.
Credit: Seacalm / Shutterstock.com.
